Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05174806 · ClinicalTrials.gov registry record · Phase 2
Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients
A Phase 2 study, sponsored by Microbion Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05174806 is a Phase 2 study that has completed, run by Microbion Corporation. The registered enrollment target is 47 participants.
The verdict
NCT05174806, a Phase 2 study, has completed, sponsored by Microbion Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a randomized, open label, controlled, multi-center study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied pravibismane (MBN-101) in patients with moderate diabetic foot infections. Patients will be randomized in a 2:1 ratio (MBN-101:standard of care). Topical pravibismane (MBN-101) will be applied three times per week for up to 12 weeks. All patients will receive systemic antibiotic treatment for a least a portion of that period. Randomization will be stratified by site.
Interventions
- OTHER Standard of Care
- DRUG Topical Pravibismane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2024-01-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05174806
The ClinicalTrials.gov registry entry for NCT05174806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Microbion Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT05174806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05174806 about?
NCT05174806 is a clinical study titled "Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients". This is a randomized, open label, controlled, multi-center study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied pravibismane (MBN-101) in patients with moderate diabetic foot infections. Patients will be randomized in a 2:1 ratio (MBN-101:standard of care...
What is the current status of trial NCT05174806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2022-06-13. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT05174806?
The interventions under investigation include: Standard of Care (OTHER), Topical Pravibismane (DRUG).
Who is sponsoring clinical trial NCT05174806?
This trial is sponsored by Microbion Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.